



THE UNITED INDUSTRY VOICE FOR AUSTRALIAN GENOMICS

July 2026 Newsletter

Dear members and friends of InGeNA,

As we move into the second half of 2026, the conversation is increasingly shifting from what genomics can achieve to how we deliver its benefits more consistently across the health system for patients. This month's activities highlight the progress being made together.

Learning from Global Leadership

At the recent pharmacogenomics presentation by Professor Sandosh Padmanabhan, *What if Every Older Adult Had Their Pharmacogenomic Profile on File?*, Scotland's experience demonstrated what is possible when pharmacogenomics is implemented at health system scale. With adverse drug reactions contributing to around one in fourteen hospital admissions, pharmacogenomics presents a significant opportunity to improve patient safety while reducing pressure on the health system. Congratulations to the myDNA team for hosting the event and for their leadership as the industry partner for the PHOENIX Study.

Preparations continue for Professor Dame Sue Hill's visit to Australia in October, one of the highlights of InGeNA's 2026 program. As the architect of the NHS Genomic Medicine Service, Professor Hill is one of the world's foremost leaders in translating genomics into routine healthcare. Her visit will provide a unique opportunity to learn from the UK's experience and strengthen international collaboration to accelerate genomics adoption in Australia. We are hosting an event in Sydney Thursday, 15 October, details to follow soon. Save the date.

The full program and engagement opportunities will be released shortly. Thank you to our sponsors AstraZeneca, AWS, Illumina, Trakgene and Genomical for their support. Sponsorship opportunities are still available, and we encourage members interested in participating to contact the InGeNA team.

From Discovery to Access

The implementation challenge and opportunity was highlighted at *From One to*

Many – Advancing Precision Therapies for Children with Rare Diseases on June 20. Congratulations to Laura Croft and her team for an inspiring event, and thank you to the families whose generosity in sharing their lived experience continues to drive meaningful change. It was wonderful to see InGeNA members AGRF Ltd and the QUT Centre for Genomics and Personalised Health supporting this important initiative. Industry play a key role the systems that translate individual breakthroughs into equitable patient access.

It was a pleasure to present to RareNET on *From Discovery to Access: How Collaboration Can Accelerate Genomics for Australian Patients*. The discussion reinforced that accelerating patient access depends on collaboration across industry, clinicians, researchers, governments and patient advocates, which remains central to InGeNA's role.

Our policy work continues to gather momentum progressing practical initiatives to improve therapeutic recommendations on oncology NGS reports, while continuing discussions on systemic improvements to MSAC processes and implementation priorities.

Local innovation support and success

Supporting Australian innovators to succeed locally and globally is central to InGeNA's mission. Thank you to Corporate Capital Group for sharing four decades of experience helping Australian companies access international markets and capital, particularly in the United States.

We also congratulate Genomical on winning the Technology Platform category at the Victorian iAwards, another example of the strength and growing maturity of Australia's genomics innovation ecosystem.

Upcoming events

Looking ahead, I will be speaking at the Translational Research Institute on 22 July (11 am-12 pm) on *Precision Medicine at Scale: Australia's Opportunity to Lead*, exploring how Australia can translate world-class genomics research into routine clinical practice. No registration required if you would like to attend.

We are also looking forward to connecting with many of you at the HGSA Annual Scientific Meeting in Christchurch, 1- 4 August. Please visit the InGeNA booth, where we will be joined by several innovators: 23Strands, Gene S, GenoCare, Genomical and Rhythm Biosciences.

Thank you to all of subscribers for your continued engagement, leadership and expertise. InGeNA's strength lies in collaborating across the ecosystem to turn innovation into implementation and equitable access to genomics and precision medicine for all Australians.

Best regards,
Erin
CEO, InGeNA

Recent Events and Member updates

🎉 **Congratulations to Oxford Nanopore Technologies** on winning the 2026 MacRobert Award, the UK's most prestigious engineering innovation prize, recognising the global impact of its pioneering nanopore sequencing technology.



myDNA CEO Alan Sheffield with Professor Padmanabhan at the Melbourne Pharmacogenomics event, July 14.



"One to Many" event June 20, Brisbane.
Erin with Dr Laura Croft and the Lipworth family



Genomical win the Technology Platform category at the Victorian iAwards July 15.



A warm welcome to our new **Associate Member: Bespoke Genetic Medicines**

Where Traditional pharmaceutical companies develop one drug for millions of patients, at Bespoke Genetic Medicines, therapies are designed and tailored to each patient's unique genetic error, one at a time.

and mobility. [Learn more](#)



We also welcome a new Partner this month: **The Institute for Biomedicine and Glycomics (IBG) at Griffith University**. IBG is a multidisciplinary biomedical research institute focused on discovering, developing and translating drugs, vaccines and diagnostics to improve health outcomes globally. [Learn more](#)



We are delighted that InGeNA has been nominated for **NGO of the Year** in the Health Industry Hub Awards 2026. This recognition belongs to our members, Board, Consumer Advisory Group and the many collaborators who continue to strengthen InGeNA's voice. Voting remains open until **3 August**, and we would greatly appreciate your support. Voting 🗳 [link](#)

Industry News

18.06.2026 Will Genomics Move From Innovation to Routine Care?

27.06.26 Australian parents' perspectives on extended genomic screening: what information to return and when?

29.06.2026 Should every baby's DNA be sequenced?

9.07.2026 Blended Genome–Exome Sequencing Slashes Costs Without Quality Loss

10.07.26 Chinese Biotech Taking Early-Phase Precision Medicine Trials to Australia Amid US Restrictions

7.07.2026 DNA diagnostics market to reach \$24.7B by 2034 on precision medicine, genomic advancements

Upcoming Events

HTAnalysts present AI in Health Innovation - Beyond the Hype

Wed, 22 Jul, 9am - 5pm AEST, Aerial Function Centre, Ultimo NSW

Moving beyond the buzz surrounding AI, this event explores the governance, regulation, and accountability, alongside how Health Technology Assessment (HTA) must evolve to evaluate AI-driven technologies. [Event link](#)

Webinar by Australian BioCommons Tuesday 11 August 2026, 1-2 pm AEST Why Research Genomics Infrastructure Must Plug Into Healthcare

As Australia invests \$200 million in precision medicine, is our research infrastructure ready? Hear from Dr Natalie Thorne, Chief Scientific Officer at Genomical, on the challenges, opportunities and what comes next. [Event Link](#)

HGSA Scientific Meeting 1-4 August 2026 at Te Pae, Christchurch New Zealand.

Australasian Genomics Technologies Association (AGTA) Conference
13-16 September, Singapore

Career opportunities

[Clinical Genomics Specialist](#) **AGRF Ltd Sydney NSW (Hybrid)**

Clinical/Medical Research (Healthcare & Medical) Full time

[Bioinformatics analyst](#) Department of Health - **Pathology Queensland**

Coopers Plains, Brisbane QLD Clinical/Medical Research (Healthcare & Medical).

[Medical Scientist](#) **Victorian Clinical Genetics Service (VCGS)**

Murdoch Children's Research Institute Parkville, Melbourne VIC

[APS Level 6 - Scientific Evaluator - Evaluation Section](#)

The office of the Gene Technology Regulator has a role in the Department of Health Disability & Ageing - Woden, Canberra ACT (Hybrid)

2026 OnQ Salary & Job Market Survey

20 years. 22,000 voices. Australia's most comprehensive **life sciences** salary dataset.
Survey takes about 11 minutes - Closes in 4 weeks - Report released September.

Responses are confidential and results are published in aggregate only.

Each year it reaches 40,000 to 50,000 professionals with up to 40% of respondents being hiring managers and key decision-makers. InGeNA members link: [Start Survey](#)

By taking part, you will:

- Benchmark your salary against your peers.
- Receive the 2026 report before it goes public.

- Contribute to two decades of data that shapes career and hiring decisions across the sector.

Join InGeNA NOW!

New Membership options and partnering opportunities

Find out more with our Membership Brochures and online
Application forms [here](#)



InGeNA Limited, 45 Brisbane Road, Suite 407 Level 4,
Mooloolaba, Queensland, 4557, Australia,

[Unsubscribe](#)

[Manage preferences](#)

Send free email today

HubSpot